{
    "Trade/Device Name(s)": [
        "UCP Drug Test Mini Cups"
    ],
    "Submitter Information": "UCP Biosciences, Inc",
    "510(k) Number": "K151213",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130463"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIO",
        "DIS",
        "JXM",
        "DJC",
        "DJR",
        "DJG",
        "LCM",
        "LDJ",
        "LFG",
        "JXN"
    ],
    "Summary Letter Date": "July 22, 2015",
    "Summary Letter Received Date": "July 23, 2015",
    "Submission Date": "July 8, 2015",
    "Regulation Number(s)": [
        "21CFR862.3100",
        "21CFR862.3150",
        "21CFR862.3170",
        "21CFR862.3250",
        "21CFR862.3610",
        "21CFR862.3620",
        "21CFR862.3650",
        "21CFR862.3870",
        "21CFR862.3910",
        "21CFR862.3700"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Barbiturates",
        "Benzodiazepines",
        "Buprenorphine",
        "Cocaine",
        "Marijuana",
        "Methadone",
        "Methamphetamine",
        "MDMA",
        "Morphine",
        "Opiates",
        "Oxycodone",
        "Phencyclidine",
        "Propoxyphene",
        "Tricyclic Antidepressant"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Cup",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for UCP Drug Test Mini Cups, a rapid, competitive binding immunoassay for qualitative detection of multiple drugs of abuse and their metabolites in urine.",
    "Indications for Use Summary": "Intended for rapid, qualitative, competitive binding immunoassay detection of multiple drugs of abuse and their metabolites in human urine for OTC or prescription use; provides preliminary screening results requiring confirmation.",
    "fda_folder": "Toxicology"
}